Clinical trials
Phase 2 Sepsis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
47 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 3 |
| 2024 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Terminated | 7 |
| Recruiting | 4 |
| Withdrawn | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 4 |
| AstraZeneca | 2 |
| Beth Israel Deaconess Medical Center | 2 |
| Vanderbilt University | 2 |
| Virginia Commonwealth University | 2 |
| AM-Pharma | 1 |
| Advanced Circulatory Systems | 1 |
| Agennix | 1 |
| Albert Einstein College of Medicine | 1 |
| Altor BioScience | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sepsis | 47 |
| Shock, Septic | 12 |
| Respiratory Distress Syndrome | 5 |
| Acute Kidney Injury | 4 |
| Acute Lung Injury | 4 |
| Infections | 4 |
| Critical Illness | 3 |
| Hypotension | 3 |
| Shock | 3 |
| Systemic Inflammatory Response Syndrome | 3 |
Trials
Showing 1 to 25 of 47. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.